Aquestive Therapeutics Inc. (NASDAQ: AQST) has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm, its investigational dibutepinephrine sublingual film for Type I allergic reactions including life-threatening anaphylaxis, reviving one of the more closely watched alternative epinephrine-delivery programs after an FDA rejection earlier this year. The September 17 filing follows months of redesign and validation work focused not on a new efficacy trial, but on an unusually practical regulatory question: whether patients experiencing a medical emergency can open the package and correctly place the film quickly enough.
Aquestive believes it has materially improved that part of the product. In a new human-factors study, revised packaging reduced the median time required for an untrained participant to open the pouch from 17 seconds in the original validation study to three seconds, while the number of participants experiencing difficulty opening it fell from 26 to one. Incorrect film placement also declined sharply, from 20 participants in the earlier study to two in the updated assessment.
The resubmission returns attention to a potentially differentiated product in a market where epinephrine auto-injectors remain widely used and ARS Pharmaceuticals’ neffy nasal spray has already established a non-injectable alternative. Anaphylm is designed as a postage-stamp-sized film placed under the tongue, requires no water or swallowing, and could become the first FDA-approved non-invasive, orally delivered epinephrine product for severe allergic reactions if the agency eventually clears it.
Why did the FDA reject Anaphylm earlier in 2026?
Aquestive originally submitted the Anaphylm NDA in March 2025 and received a Complete Response Letter from the FDA on January 30, 2026. The agency did not approve the product because its review identified deficiencies involving human factors and requested additional pharmacokinetic work, according to the company. Importantly for interpreting the setback, Aquestive said the CRL did not identify chemistry, manufacturing and controls deficiencies and did not challenge several comparability datasets already included in the original application.
One concern involved participants who struggled to open the Anaphylm pouch during human-factors testing. Another involved patients placing the film incorrectly inside the mouth, an issue that can be particularly consequential when treating anaphylaxis because delays or incorrect administration can reduce the usefulness of an emergency medicine precisely when rapid treatment matters most. The company said the FDA viewed the observed human-factors problems as potentially significant safety issues if they remained unresolved.
The agency therefore requested that Aquestive revise the packaging, instructions and labeling, validate the redesigned user interface and conduct a supportive pharmacokinetic study. Aquestive subsequently held a Type A meeting with the FDA in March and received additional human-factors protocol guidance in June before carrying out the studies supporting the September resubmission.
That sequence makes the second review different from the original submission. The core question is now whether the regulator agrees that the redesigned product and additional clinical pharmacology evidence adequately resolve the issues specified in the Complete Response Letter, rather than whether Aquestive has simply returned with substantially the same package.
How much did Aquestive improve the Anaphylm packaging and administration process?
The numerical change in user performance is one of the strongest features of the resubmission. In the original human-factors validation study involving 166 participants, 26 experienced difficulty opening the pouch in ways that could potentially delay administration, prevent delivery or contribute to underdosing. One participant was unable to open the pouch, six films were torn during opening, and 20 participants incorrectly positioned the film inside the mouth.
In the updated 105-person study, no participant was unable to open the redesigned pouch and only one experienced opening difficulty. No films were torn, two participants incorrectly positioned the film, and the behaviors previously observed in which patients chewed or removed the film were not seen in the new validation study. Median time for an untrained participant to open and administer the first dose fell from 46 seconds in the earlier study to 17 seconds after the redesign.
The company also studied self-administration more directly. In a 24-person pharmacokinetic study arm, all participants opened the pouch, removed the film and placed it under the tongue as expected without clinician assistance. None tore or dropped the film during opening, and none removed it after administration, according to data Aquestive submitted in its regulatory materials.
These results do not guarantee FDA approval, and Aquestive itself cautioned that the studies do not establish regulatory adequacy or final approval. They nevertheless address the specific operational deficiencies that played a major role in January’s rejection and provide the FDA with new evidence on whether the product can be used reliably outside a controlled clinical setting.
What exactly is Anaphylm and how would it differ from epinephrine auto-injectors?
Anaphylm is a polymer-matrix sublingual film containing dibutepinephrine, an epinephrine prodrug. The product is designed to be placed under the tongue, where it begins dissolving on contact, and does not require a patient to swallow a tablet, use water, manipulate a syringe or operate a mechanical injection device. Aquestive describes the film as roughly comparable in size to a postage stamp, while its primary packaging is thinner and smaller than an average credit card.
The commercial rationale centers partly on treatment hesitation. Anaphylaxis can progress rapidly, yet patients may not always administer injectable epinephrine promptly because of needle anxiety, uncertainty about device use, inconvenience or failure to carry an auto-injector consistently. Removing the needle and reducing device complexity could potentially address some of those barriers, although actual uptake would depend on FDA labeling, physician confidence, payer coverage and real-world patient preferences.
Aquestive is no longer trying to enter a market consisting only of injectable products. The FDA approved ARS Pharmaceuticals’ neffy epinephrine nasal spray in August 2024 for adults and pediatric patients weighing at least 30 kilograms, creating the first non-injectable FDA-approved epinephrine product for anaphylaxis. The agency subsequently expanded neffy’s use in March 2025 to children aged four years and older weighing between 15 and 30 kilograms.
That changes Anaphylm’s potential positioning. The competitive proposition is no longer simply “needle-free versus injection,” but rather whether an orally delivered, device-free film offers sufficient portability, speed, reliability and usability to differentiate itself from both established auto-injectors and an approved nasal option.
Why is ease of use such a significant regulatory issue in anaphylaxis?
Anaphylaxis is a severe systemic allergic reaction that can involve breathing difficulty, swelling, vomiting, cardiovascular instability or loss of consciousness and may worsen rapidly after exposure to foods, medications, insect stings or other allergens. Epinephrine is the standard emergency treatment, meaning a delivery system must work not only under ideal conditions but also when patients or caregivers may be frightened, hurried or unfamiliar with administering the product.
That helps explain why difficulties opening a pouch can become a regulatory issue rather than merely a packaging inconvenience. A difference of several seconds may have limited consequence for many routine medicines, but emergency therapies require regulators to consider whether real-world usability could delay effective treatment or result in an incorrect dose. The FDA’s January response therefore placed substantial emphasis on human factors even though Aquestive said the agency did not raise new chemistry, manufacturing or broader clinical-efficacy concerns.
Aquestive’s redesign appears intended to reduce the number of steps or opportunities for error between recognizing an allergic reaction and delivering the film. The improved study results provide evidence that participants can open and administer the revised product more consistently, but the FDA must now determine whether those improvements satisfy the standard required for approval of an emergency medicine.
The agency will also assess the confirmatory pharmacokinetic information included with the resubmission. Aquestive reported that self-administered Anaphylm produced pharmacokinetic findings comparable with clinician-administered dosing and said the additional study incorporated intramuscular epinephrine as a comparator.
What happens now that Aquestive has resubmitted the Anaphylm NDA?
The immediate regulatory milestone is the FDA’s classification of the resubmission. The agency must first determine whether Aquestive’s response is considered a Class 1 or Class 2 resubmission and establish the corresponding review timeline. Aquestive has said it intends to request expedited review, although the company has explicitly cautioned that an accelerated timeline is not guaranteed.
A Class 1 resubmission generally involves a shorter review cycle than a Class 2 response, so the agency’s classification will provide an early indication of how regulators view the scope of the company’s corrective work. Until that determination is made, Aquestive does not have a new publicly established FDA action date for Anaphylm.
The company is simultaneously working on international expansion. Recent corporate materials indicate plans for a Canadian filing before the end of 2026 and a European Union submission during the first quarter of 2027, suggesting management is attempting to develop Anaphylm as a broader commercial franchise rather than a U.S.-only product.
Commercial preparation is also underway before any final FDA decision. Aquestive said during its second-quarter update that it was continuing medical-affairs activities and payer engagement, allowing the company to build awareness and reimbursement infrastructure while the regulatory process continues.
Does Aquestive have enough cash to prepare for an Anaphylm launch?
Aquestive reported $98.5 million in cash and cash equivalents at June 30, 2026. Second-quarter revenue increased 38% year over year to $13.8 million from $10 million, driven primarily by manufacturing and supply revenue as well as increased license and royalty income.
The company remains loss-making as it funds development and prepares for potential commercialization. Research and development expenses were $4 million during the second quarter, while selling, general and administrative expenses reached $14.1 million as pre-launch and corporate spending continued. Adjusted EBITDA loss improved to $5.2 million from $9.3 million in the comparable 2025 quarter.
Aquestive maintained full-year guidance calling for $46 million to $50 million in revenue and an adjusted EBITDA loss of $30 million to $35 million. The balance sheet therefore provides the company with resources to continue the regulatory process and launch preparation, although a full commercial introduction would introduce additional spending on market access, sales infrastructure, inventory and physician education.
Anaphylm’s regulatory outcome is consequently important not only clinically but financially. Approval would potentially transform Aquestive from a business still heavily dependent on manufacturing, licensing and royalty revenue into one with a proprietary emergency-allergy product positioned for direct commercialization.
Why did AQST stock fall despite the Anaphylm resubmission?
The market reaction has been notably restrained. Aquestive shares closed at $4.66 on September 17, down 3.32% on the day the resubmission was announced, and declined another 1.07% to $4.61 on September 18. Trading volume reached approximately 2.5 million shares on September 17 and 3.5 million the following day, leaving the company’s market capitalization at roughly $579 million at the latest close.
The reaction suggests that simply resubmitting the application was not sufficient to resolve the uncertainty created by the January Complete Response Letter. Aquestive had previously guided investors toward a third-quarter resubmission, and the successful completion of its human-factors and pharmacokinetic work had already been announced in August. Much of the September filing was therefore an expected milestone rather than an unexpected clinical breakthrough.
Attention is now likely to move toward the FDA’s classification of the submission and eventual action date. Those developments will provide more information on how long investors, physicians and potential commercial partners must wait before knowing whether Anaphylm can enter the increasingly competitive epinephrine rescue market.
Could Anaphylm reshape the needle-free epinephrine market if approved?
The opportunity is broader than simply replacing one delivery device with another. The development of neffy and Anaphylm reflects an industry effort to reduce practical barriers surrounding epinephrine, particularly the reluctance some patients experience around injections and the challenge of carrying emergency treatment consistently.
Neffy’s approval demonstrated that the FDA is willing to evaluate non-injectable epinephrine using pharmacokinetic and pharmacodynamic bridging evidence rather than requiring patients experiencing actual anaphylaxis to be randomized during life-threatening episodes. Anaphylm is attempting to extend that evolution into an oral-film format while maintaining the rapid systemic exposure needed for emergency use.
Commercial differentiation will nevertheless require more than approval. Aquestive would need to persuade allergists, patients, caregivers and payers that carrying a sublingual film offers meaningful advantages over nasal spray and established auto-injectors while providing reliable exposure under the conditions in which an emergency product is actually used.
The redesigned pouch has therefore become more consequential than packaging might initially suggest. The January CRL demonstrated that a promising drug-delivery concept can be delayed by seemingly simple real-world usability problems, while the September resubmission puts Aquestive in position to test whether those problems have now been adequately resolved.
The next decisive signal will come from the FDA rather than from another company-run trial. Once the agency classifies the resubmission and establishes its review schedule, the market should have a clearer timeline for determining whether Anaphylm can move from an investigational postage-stamp-sized film into a commercial competitor in emergency allergy treatment.
